941 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 1,262 published third-party lab tests of Semaglutide across 314 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.55%. Within this published corpus, 3 positive purity results were below 90%, and 57 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
As of 2026-09-04, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $7.33 | $5.50–$10.50 | $1.47 | 3 sources · 3 offers |
| 10 mg | $11.17 | $8.00–$16.00 | $1.12 | 3 sources · 3 offers |
| 15 mg | $16.33 | $10.00–$29.00 | $1.09 | 3 sources · 3 offers |
| 20 mg | $15.67 | $11.50–$22.50 | $0.78 | 3 sources · 3 offers |
| 30 mg | $155.00 | $155.00–$155.00 | $5.17 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 226 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 29 | 99.43% | 0 of 29 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 30 | 99.43% | 0 of 26 (0.0%) 0 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → | |
| #3 | 25 | 99.55% | 0 of 25 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #97734 (99.9%) · #96281 (99.9%) · #96282 (99.9%) · #74761 (99.107%) · #82240 (99.218%) · #86130 (99.94%)
If successful, this trial could establish **semaglutide** as a novel therapeutic strategy to mitigate severe GI complications associated with auto-HSCT, significantly improving patient quality of life and reducing inf…
This Phase II trial is crucial for advancing treatment options for **MASH** and **obesity**, conditions with significant unmet medical needs. **If successful**, the combination of **CS060380** with semaglutide could o…
This research significantly advances our understanding of how `GLP-1RAs` like **semaglutide** exert their neuroprotective effects, moving beyond general anti-inflammatory observations to specific cellular and transcri…
This large real-world study provides compelling evidence for the broad metabolic benefits of **oral semaglutide** in routine clinical practice, extending beyond glycemic control and weight loss to include significant …
This study provides critical insights for clinicians and individuals using **semaglutide** for **T2DM** management. **Patients with a normal BMI or lower baseline HbA1C (<7) require heightened vigilance for hypoglycem…
This preclinical study offers a promising strategy for individuals using GLP-1RAs like semaglutide to manage **obesity**, particularly for those concerned about **muscle loss**. **Co-administering ketone esters could …
Elecoglipron, an oral small molecule `GLP-1` receptor agonist, was evaluated for efficacy, safety, and tolerability in a 26-week Phase 2b trial for **type 2 diabetes**.
This study underscores a critical need for enhanced digital health literacy among individuals seeking information on **semaglutide** for weight loss. **Viewers should prioritize content from academic or healthcare-aff…
This research highlights a critical safety concern for patients on GLP-1 receptor agonists like semaglutide who require anesthesia. **Anesthesiologists may need to adapt pre-operative fasting guidelines or implement a…
The ongoing investigation of **NNC0662-0419** represents a crucial step in potentially expanding the therapeutic arsenal for **Type 2 Diabetes**. If proven effective and safe, this novel compound could offer a new opt…
**Understanding drug-drug interactions is paramount for safe and effective patient care.** If semaglutide significantly alters the pharmacokinetics or pharmacodynamics of **warfarin**, dosage adjustments or increased …
**Direct comparison of Lactobacillus paracasei LC-19 and semaglutide** for weight management and metabolic health is significant. The findings could **inform individualized intervention strategies**, offering a potent…
If successful, **ACM-001.1** could significantly improve the quality of weight loss achieved with semaglutide, shifting the focus from mere weight reduction to optimized body composition. This would be a major step to…
This study aims to provide crucial **real-world validation** for **semaglutide** dose escalation from **0.5 mg** to **1.0 mg** weekly. For clinicians and individuals managing **Type 2 Diabetes**, robust real-world dat…
This real-world retrospective study reinforces the established efficacy and safety profile of weekly injectable semaglutide in a diverse patient population, specifically within a tertiary care setting in Pakistan. **F…
This re-analysis suggests that the initial declaration of failure for **semaglutide** in **Alzheimer's disease** may have been premature, highlighting the importance of evaluating longer-term data. **For individuals e…
This real-world comparison provides valuable insights for clinicians and patients weighing options for **obesity** management. **ESG offers a more rapid and pronounced initial weight loss effect compared to oral semag…
This study provides compelling evidence that GLP-1RAs may offer significant protective benefits against a range of age-related ocular diseases in non-diabetic older adults with obesity. **For individuals using GLP-1RA…
This research provides a crucial neural map of the DVC and pinpoints a specific, conserved pathway for cagrilintide's long-term metabolic benefits. **Understanding that cagrilintide's effects are mediated through `Prl…
**Clinicians should consider diabetes status and specific GLP-1 agent selection when prescribing for weight loss.** Non-diabetic individuals may expect substantially greater weight reduction, potentially influencing t…
This case underscores the importance of early diagnosis and a multi-pronged therapeutic approach for **Type B insulin resistance (TBIR)**, especially in atypical presentations. **Integrating GLP-1 receptor agonists li…
These findings suggest that **GLP-1 receptor agonists like semaglutide could serve as a novel adjunctive therapy to improve surgical outcomes in diabetic patients**, particularly those undergoing spinal procedures. Be…
**This study validates a locally developed semaglutide injection as an equally effective and safe alternative to the reference biologic for Indian T2DM patients.** This is a critical step towards enhancing access to `…
This commentary offers crucial reassurance for individuals using **semaglutide** for weight management and for clinicians prescribing it. **The finding that semaglutide-induced lean mass loss adapts and may not cause …
**Emergency physicians should be aware that semaglutide overdose can present with isolated neurologic symptoms like dysesthesia and asthenia, which may follow a benign, self-limited course.** This case expands the kno…
Semaglutide-induced weight loss is significantly reduced in obese patients who are diabetic, older, or of Hispanic ethnicity.
**Early generic semaglutide availability in Canada offers a critical case study for improving drug access and affordability in the US.** For US patients and biohackers, this research highlights the potential for signi…
If this trial demonstrates that **semaglutide** significantly reduces both body weight and knee pain in individuals with obesity and OA, it could represent a major advancement in treatment. **This could establish sema…
A clinical trial aims to assess semaglutide's efficacy on body weight, insulin dose, glucose control, and safety in Type 1 Diabetes patients.
A Phase 3 trial will compare XW003 injection against semaglutide injection for efficacy and safety in Chinese adults with obesity.
NNC0194-0499 and semaglutide, alone or combined, are being investigated in a clinical trial for reducing liver damage in **NASH** patients.
**If successful, this trial could significantly expand semaglutide's indication to a broader population of obese individuals without diabetes**, offering a powerful new pharmacological tool for weight management. Curr…
Understanding semaglutide's direct impact on renal hemodynamics and specific physiological markers like `RAAS` activity and `GFR` is crucial for optimizing its use in **type 2 diabetes mellitus (T2DM)** patients with …
**Collecting real-world data on semaglutide's performance in Type 2 Diabetes is vital for clinicians and patients.** This observational study will provide valuable insights into how **semaglutide** functions outside t…
This prospective observational study is crucial for understanding how **Wegovy** performs in diverse, real-world settings, beyond the controlled environment of randomized clinical trials. **The findings will provide v…
This study is highly relevant for expanding access to effective **T2DM** and obesity management. **The availability of a novel, potentially more affordable semaglutide formulation could significantly improve treatment…
**Semaglutide** users and clinicians should understand that while weight loss is beneficial, the accompanying lean mass reduction needs careful evaluation. This commentary highlights the ongoing debate: is the muscle …
Semaglutide's impact on inflammatory features in spinal implant-associated infection was explored across Type 1 and Type 2 diabetes models, addressing distinct disease pathologies.
This case report significantly expands the known adverse effect profile of semaglutide, particularly at supratherapeutic doses. **Emergency physicians should consider isolated neurologic symptoms like prolonged dysest…
If successful, this study could establish **Cagrilintide-semaglutide** (CagriSema) as a valuable add-on therapy for **type 2 diabetes** patients whose glycemic control remains inadequate despite basal insulin. **This …
This research highlights a significant advancement for individuals with **type 2 diabetes** who struggle with weight management and glycemic control. The substantial weight loss achieved with **cagrilintide-semaglutid…
While specific findings are pending, this phase 3 study design for CagriSema is highly significant for **type 2 diabetes** and **obesity management**. The combination of a **GLP-1 receptor agonist** (semaglutide) and …
The initiation of a Phase 3a trial for **CagriSema** marks a significant step towards a potentially more effective treatment for **type 2 diabetes** and **weight management**. This combination of a `GLP-1 receptor ago…
**Semaglutide's role in improving reproductive health for women with PMOS and obesity offers a significant new therapeutic avenue beyond its primary use for diabetes and weight management.** This finding suggests that…
The rapid and substantial increase in GLP-1RA use among youth, particularly for weight management, underscores an urgent need for refined clinical protocols. **Clinicians must ensure specialist involvement in initiati…
This study provides crucial health economic evidence for the adoption of **semaglutide 2.4 mg** within the Spanish public health system. **For clinicians and policymakers, it validates semaglutide 2.4 mg as a cost-eff…
**Optimizing oral semaglutide formulations could significantly enhance patient adherence and expand access to this highly effective GLP-1 receptor agonist.** Improved bioavailability and reduced administration complex…
This study highlights that **demographic and clinical factors significantly influence semaglutide's real-world weight loss efficacy, necessitating personalized treatment expectations.** For clinicians and individuals …
This large cohort study provides crucial real-world evidence confirming an increased risk of gallstones and related complications with GLP-1 RA use in **T2DM** patients. **Clinicians prescribing GLP-1 RAs should couns…
This study is critical for understanding how **semaglutide** performs in specific East Asian populations, potentially informing more tailored treatment protocols for **obesity**. If positive, the findings could **expa…
Free, no account — handy when you're working with Semaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account